 Home > Active Ingredient News > Immunology News > Milestone progress in allergic diseases, the world's first Artemisia pollen sublingual immunotherapy drug was launched

Milestone progress in allergic diseases, the world's first Artemisia pollen sublingual immunotherapy drug was launched

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

south african companies

sodium chloride allergy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Artemisia annua, istock

April 2, 2021, China sublingual desensitization Forum in Shanghai was held, the forum announced the world's first for the treatment of Artemisia annua allergic rhinitis / mugwort pollen allergy caused by (or associated with conjunctivitis) of standardization The desensitization drug- Artemisia annua pollen allergen sublingual drops was approved for marketing.

Too allergic diseases affecting human health of major diseases , allergic diseases is the world's sixth largest chronic disease , the World Health Organization allergic diseases asone of the key research and disease prevention in the 21st century,Beijing Tongren Hospital Dean Professor Zhang Luo said: "Allergic rhinitis (i.

Too allergic diseases are major diseases affecting human health through the allergic diseases are major diseases affecting human health through the allergic diseases are major diseases affecting human health ofallergic diseases , , allergic diseases, chronic diseases are the world's sixth largest , world The Health Organization lists allergic diseases as the sixth largest chronic disease in the world .

In China, pollen is the main inducing factor of allergic diseases.

Lou, H.

There are obvious differences in allergens between North and South in China.

The south is to mites as a major allergen, Artemisia annua pollen allergen sublingual drops

In the past, the treatment of allergies mainly relied on "temporary treatment" to relieve symptoms, such as the use of antihistamines, nasal spray hormones and other symptomatic drugs.

Desensitization mechanism and classification, CNKI, Head Leopard Research Institute

Desensitization therapy, also known as specific desensitization therapy, is a treatment method for allergic diseases that is stimulated by multiple allergens to promote the immune system of the body to produce immune tolerance .

Professor Zhang Luo, dean of Beijing Tongren Hospital affiliated to Capital Medical University, said in an exclusive interview with Metz Medicine that the current desensitization treatment mainly includes subcutaneous injection desensitization and sublingual desensitization.

"China Guidelines for Sublingual Immunotherapy for Allergic Rhinitis and Allergic Asthma" and SLIT treatment process, J Thorac Dis 2019;11(12):4936-4950, http://dx.

In January 2020, Chinese Medical Association allergy credits (CSA) released the first "allergic rhinitis and allergic asthma sublingual immune therapy China Guide" , covers covers covers the epidemiology of allergic rhinitis and allergic asthma , Sublingual immunotherapy mechanism, indications and contraindications, standardized allergen preparations, standardized sublingual immunotherapy development, efficacy evaluation and adverse event management, etc.

Artemisia annua pollen allergen sublingual drops is a sublingual drug that is administered under the tongue.
It is a desensitization treatment for specific allergens.
It is clinically used to treat Artemisia annua /Mugwort pollen allergy after allergen detection.
For adult allergic rhinitis (or conjunctivitis), it is recommended to start the treatment at least 4 months before the expected annual pollen season of Artemisia annua/Artemisia wormwood, and continue to use it throughout the pollen season.
No symptoms in the non-pollen season It is necessary to adhere to the medication, and the effect is more stable.
It is recommended to use it continuously for at least 3 years .
The latest research data shows that long-term desensitization treatment can effectively prevent re-allergies in the pollen season in the coming year.

The effect of multicenter sublingual immunotherapy of Artemisia annua on the daily comprehensive score of drugs and rhinoconjunctivitis symptoms

(CSMRS), Lou et al.
World Allergy Organization Journal (2020) 13:100458, http://doi.
org/10.
1016/j.
waojou.
2020.
100458

The approval of the new drug is based on important data obtained from the Phase III clinical trial led by Professor Zhang Luo, Dean of Beijing Tongren Hospital Affiliated to Capital Medical University.
The Phase III clinical trial of Artemisia annua pollen allergen sublingual drops is a multi-center, randomized trial.
, Double-blind, placebo-controlled trial, 13 13 13 centers enrolled a total of 702 subjects, randomly divided into experimental group (468 people) and placebo group (234 people).
The test results showed that compared with the placebo group, the 32-week standardized Artemisia annua drops sublingual desensitization treatment can significantly improve the patients' nasal symptoms and reduce the use of symptomatic drugs.
A total of 702 subjects were enrolled in the home center, and they were randomly divided into a trial group (468 people) and a placebo group (234 people).
The test results showed that compared with the placebo group, the 32-week standardized Artemisia annua drops sublingual desensitization treatment can significantly improve the patients' nasal symptoms and reduce the use of symptomatic drugs.

Artemisia annua‐sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial, First published: 07 February 2020 org/10.
1111/all.
14218">https://doi.
org/10.
1111/all.
14218org/10.
1111/all.
14218"> https://doi.
org/10.
1111/all.
14218 https:/ /doi.
org/10.
1111/all.
14218

Another single-center randomized double-blind placebo-controlled trial showed that standardized Artemisia annua sublingual desensitization treatment can improve the immunological indicators of patients.
After the drug is stopped, it can continue to improve the symptoms of patients and reduce the incidence of new diseases.
Increasing the probability of allergens shows that Artemisia annua sublingual desensitization treatment has long-term curative effect and preventive effect.

Standardized Artemisia annua sublingual desensitization treatment can improve the patient's immunological indicators.
After the drug is stopped, it can continue to improve the patient's symptoms and reduce the probability of patients with new allergens.
This shows that Artemisia annua sublingual desensitization treatment It has long-term curative effect and preventive effect.
Standardized Artemisia annua sublingual desensitization treatment can improve the patient's immunological indicators.
After the drug is stopped, it can continue to improve the patient's symptoms and reduce the probability of patients with new allergens.
This shows that Artemisia annua sublingual desensitization treatment It has long-term curative effect and preventive effect.

Cover of China Special Issue of "Allergy" Magazine

Professor Zhang Luo pointed out that China’s clinical academic research on allergy has made considerable progress and has participated in many international English version of the diagnosis and treatment guidelines.
It is worth mentioning that in February 2021, the international high-impact journal in the field of allergy and immunity-"Allergy" ( Allergy has specially launched China issue, which includes important articles recently published by many Chinese scholars in Allergy magazine, which also shows that China's clinical research is internationally recognized.
At the same time, Professor Zhang Luo also pointed out that China’s allergic diseases still have to be solved by themselves.

Professor raise pointed out that China allergy clinical academic research have made great progress, participated in many international English version diagnosis and treatment guidelines, China allergy clinical academic research have made great progress, participated in many international English version diagnosis and treatment guidelines, Chinese academic clinical allergy research by leaps and bounds development, participated in many international English version of treatment guidelines, treatment is worth mentioning that, in February 2021, the international high-impact journals in the field of allergy and immune - "allergy" magazine (allergy) special issue will introduce China (China issue), It includes many important articles recently published by Chinese scholars in Allergy magazine, which also shows that China's clinical scientific research is internationally recognized.
At the same time, Professor Zhang Luo also pointed out that China’s allergic diseases still have to be solved by themselves.
It is worth mentioning that in February 2021, Allergy, an international high-impact journal in the field of allergy and immunity, launched a special China issue, which includes many Chinese scholars’ recent publications in Allergy.
An important article, which also shows that China's clinical scientific research is internationally recognized.
At the same time, Professor Zhang Luo also pointed out that China’s allergic diseases still have to be solved by themselves.
At the same time, Professor Zhang Luo also pointed out that China’s allergic diseases still have to be solved by themselves.

Chinese scholars published in Allergy Magazine 2019, Allergy.
2021;76:422–424.

An editorial issued by Allergy magazine pointed out that in the field of allergy, Artemisia was first reported as the most important source of allergic pollen in northern China in the early 1950s.
Since then, the prevalence of allergic diseases and the consequent socio-economic burden has increased greatly.
This has led to many studies evaluating the epidemiology, pathogenesis, diagnosis and treatment strategies of allergic diseases, which has made significant progress in this field.
In the past 70 years, Chinese scientists have made great contributions to the global understanding of allergies.
In the field of allergy, Artemisia was first reported as the most important source of allergic pollen in northern China in the early 1950s.
Since then, the prevalence of allergic diseases and the consequent socio-economic burden has increased greatly.
This has led to many studies evaluating the epidemiology, pathogenesis, diagnosis and treatment strategies of allergic diseases, which has made significant progress in this field.
In the past 70 years, Chinese scientists have made great contributions to the global understanding of allergies.
In the past 70 years, Chinese scientists have made great contributions to the global understanding of allergies.

On the other hand, my country has also made breakthroughs in the commercialization of drug treatments for allergic diseases.
The research and development of this drug for allergic diseases has been selected as a major national new drug creation project and has been given priority review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
qualifications.
The launch of the new drug may bring significant clinical benefits to many domestic patients suffering from Artemisia pollen allergies, and effectively improve the prognosis of patients and enhance the quality of life.

The launch of the new drug may bring significant clinical benefits to many domestic patients suffering from Artemisia pollen allergies, and effectively improve the prognosis of patients and enhance the quality of life.
The launch of the new drug may bring significant clinical benefits to many domestic patients suffering from Artemisia pollen allergies, and effectively improve the prognosis of patients and enhance the quality of life.

references:

References: References:

1.
Sensitization patterns and minimum screening panels for aeroallergens in self-reported allergic rhinitis in China, 2017.

2.
Lou H, et al.
Artemisia Annua sublingual immunotherapy for seasonal allergic rhinitis: A multicenter, randomized trial.
World Allergy Organ J.
2020, 13(9): 100458.

3.
Lou H, Huang Y, Ouyang Y, et al.
Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial.
Allergy, 2020, 75(86).

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.